LAM
EBS icon

L2 Asset Management’s Emergent Biosolutions EBS Stock Holding History

L2 Asset Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149K Sell
17,769
-8,013
-31% -$67K 0.02% 403
2026
Q1 		$214K Buy
25,782
+15,181
+143% +$157K 0.02% 372
2025
Q4 		$131K Buy
10,601
+421
+4% +$4.51K 0.02% 359
2025
Q3 		$89.8K Sell
10,180
-1,782
-15% -$13.9K 0.01% 360
2025
Q2 		$76.3K Buy
+11,962
New +$68.5K 0.01% 357

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

L2 Asset Management's EBS Position: Q2 2026 in Review

L2 Asset Management reduced its Emergent Biosolutions (EBS) stake by 31% in Q2 2026, selling an estimated $67K and leaving 17,769 shares worth $149K. The position accounts for 0.02% of the portfolio, ranked #403.

L2 Asset Management first reported a position in EBS in Q2 2025 and has held it in 5 quarters since. The position peaked at $214K in Q1 2026. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • L2 Asset Management held 17,769 shares of Emergent Biosolutions worth $149K as of Q2 2026.
  • L2 Asset Management sold 8,013 Emergent Biosolutions shares in Q2 2026, an estimated $67K.
  • Emergent Biosolutions made up 0.02% of L2 Asset Management's portfolio in Q2 2026, its #403 holding.
  • L2 Asset Management first reported a position in Emergent Biosolutions in Q2 2025 and has held it in 5 quarters since.
  • L2 Asset Management's Emergent Biosolutions position peaked at $214K in Q1 2026.
  • 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on L2 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.